Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

In vitro assays for investigating the immunomodulatory properties of human mesenchymal stromal cells.

Lethager LL., Bangsgaard S., Mønsted Johansen E., Ali Qayyum A., Pravsgaard Christensen J., Ekblond A.

Narrative Review on Immune Modulation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Stem Cell Res Ther (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41654965
PMCID
PMC12977495
DOI
10.1186/s13287-026-04920-x

Abstract (original English)

Mesenchymal stromal cells (MSCs) are widely recognized for their immunomodulatory properties, which underpin their therapeutic potential in inflammatory and immune-mediated diseases. Although MSC therapies have consistently proven safe, clinical efficacy remains inconclusive, maybe due to incomplete understanding of MSC interactions with the immune environment. This review evaluates current trends in MSC immunomodulation research, based on 318 studies published since 2019 until medio 2024. The most frequently used assays included characterization, proliferation, and polarization, employing methods such as flow cytometry, enzyme-linked immunosorbent assays and colorimetric assays, and polymerase chain reaction. Many studies incorporated strategies for priming of MSCs or included immune cells, most commonly peripheral blood mononuclear cells, T cells, and macrophages. We identify key sources of variability and propose a minimum reporting checklist including MSC source, priming conditions, assay design, and immune cell characteristics. We further recommend implementation of multi-assay workflows combining phenotypic characterization with at least one functional assay. These measures may improve transparency, comparability across studies, and guide robust assay design.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMesenchymal Stem CellsImmunomodulationCell Proliferation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research